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Abstract
Atherosclerosis is a chronic inflammatory disease with complex pathological processes. MicroRNA-33 (miR-33), a
novel non-coding RNA that coexpresses with sterol regulatory element-binding proteins (SREBPs), affects
macrophage actions to prevent atherosclerosis. Fibroblast growth factor 21 (FGF21) is an important regulator of
lipid metabolism, especially for macrophage-related cholesterol export, but the mechanism is not fully studied.
Interestingly, FGF21 has been evidenced to prevent atherosclerosis via inhibiting SREBP-2 expression. Therefore, we
speculate that FGF21 may be a potential regulator for miR-33 with an aim of insight into novel anti-atherosclerotic
mechanisms and research fields.
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Introduction
Atherosclerosis is a chronic inflammatory disorder char-
acterized by the deposition of excess lipids in the arterial
intima. Reverse cholesterol transport (RCT) could coun-
teract the pathogenic events by promoting cholesterol
efflux to high-density lipoprotein (HDL) from the artery
wall, which involves in a series of factors including
macrophage or non-macrophage related cholesterol
efflux, cell membrane bound transporters, plasma lipid
acceptors, plasma proteins and enzymes, and hepatic
cellular receptors [1]. Macrophages exert important roles
in cholesterol efflux and preventing atherosclerosis.
Cholesterol efflux from atherosclerotic plaque is a
featured function of macrophage, which is determined
by two critical transporters on the membrane. One is
ATP-binding cassette transporter A1 (ABCA1), mainly
interacting with cholesterol-deficient and phospholipid-
depleted apolipoproteinA-I (apoA-I) complexes. The
other is ATP-binding cassette transporter G1 (ABCG1)
that mediates macrophage cholesterol efflux through
interacting with spherical, cholesterol-containing alpha
HDL particles [1]. Hence, increasing the two
transporters on macrophages is critical to promoting
RCT process and reversing atheroma.
Inflammation response is of central importance for the
initiation and progression of atherosclerosis. Macro-
phage counts in symptomatic carotid plaques are signifi-
cantly increased and considered to discriminate between
symptomatic and asymptomatic patients [2]. Moreover,
macrophage phenotypes have been identified as important
factors in atherosclerotic conditions [3]. Accordingly,
macrophages in atherosclerotic plaque are divided as pro-
and anti-inflammatory macrophages, with polarization
phenotypes M1 and M2 macrophages respectively. Both
the two kinds of macrophages are hallmarks of athero-
sclerotic lesions. M1 macrophages are the predominant
phenotype in rupture-prone shoulder regions while M2
macrophages present more stable of atherosclerotic
plaque and prevent foam cell formation [3, 4]. It has been
found that macrophages could alter their phenotypes and
functions in response to certain stimulators or cytokines
[5]. Thus, regulators to increase anti-inflammatory macro-
phages and decrease pro-inflammatory macrophages
within atherosclerotic lesions are promising approaches to
prevent atherosclerosis and plaque rupture.
MicroRNAs (miRNAs) are small, non-coding RNAs that
regulate gene expression and control a wide range of
biological functions by base pair with specific mRNAs.
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Recent reports have identified specific miRNAs as major
regulators of lipid homeostasis and anti-atherosclerosis;
and the best-characteristic one is miRNA-33 (miR-33) [6].
Although several recent findings reported that suppres-
sion of miR-33 is controversial in lipid metabolism and
anti-atherosclerosis [7–9], more studies evidenced that
inhibiting miR-33 could improve lipid profile and have
atheroprotective properties. Rayner et al. [10] demon-
strated that inhibition of miR-33 stabilized atherosclerotic
plaques, and anti-miR-33–treated mice showed 35% re-
duction in plaque size and lipid content after 4 weeks,
which was consistent with the levels of increased circulat-
ing HDL and enhanced RCT to plasma, liver, and feces.
Rotllan et al. [11] further reported that long-term
anti–miR-33 therapy for 12 weeks also significantly
reduced the progression of atherosclerosis in low-density
lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice model.
Well-documented evidences of miR-33-induced anti-
atherosclerotic mechanisms are focused on regulating
macrophage actions. MiR-33 was reported to inhibit the
expression of ABCA1 and ABCG1 in macrophages,
thereby attenuating cholesterol efflux to apoA-I and nas-
cent HDL [12]. While inhibiting miR-33 increases macro-
phage related cholesterol efflux by upregulating the
expression of ABCA1 and ABCG1. Rayner et al. [10]
found that anti-miR33–treated 4 weeks had a 66% in-
crease in lesional macrophage ABCA1 expression com-
pared with these control groups in mice. Besides, miR-33
was also identified to regulate macrophage polarization
and thereby stabilizing atherosclerotic plaque to reduce
cardiovascular events. Ouimet et al. [13] reported that
in Ldlr-/- mice model, inhibition of miR-33 could
delay progression of atherosclerosis by inhibiting
monocyte recruitment and changing macrophage-
induced inflammation in atherosclerotic plaques,
which was independent of the effect of ABCA1 in-
duced cholesterol export. Thus, inhibiting miR-33
could promote macrophage conversion from pro-
inflammatory M1 to anti-inflammatory M2 phenotype
to prevent atherosclerosis and stabilize plaque.
Fibroblast growth factor 21 (FGF21), a member of the
fibroblast growth factor (FGF) family, has been described
as an important regulator of glucose and lipid metabol-
ism [14–16]. Recently, serum FGF21 levels was found
positively related to coronary heart disease (CAD) and
atherosclerosis. Chow et al. [17] in a cohort consisted of
670 subjects found that serum FGF21 levels positively
correlated with carotid atherosclerosis in humans on
multiple stepwise regression analysis. In another cohort
study with 253 subjects, Shen et al. [18] further observed
that subjects with CAD showed significantly higher
serum FGF21, which was also positively correlated with
total cholesterol (P < 0.05) and triglyceride (P < 0.01).
Thus, serum FGF21 elevation under atherosclerosis
conditions may be a regulatory compensation mechan-
ism and indicate a promising therapeutic target.
Mechanically, FGF21 was also received wide attention
in the effect of macrophage-derived cholesterol efflux.
Shang et al. [19] found that in vitro treatment with FGF21
at 50 and 100 ng/mL significantly enhanced cholesterol ef-
flux compared with the control group (P < 0.05); and this
process was related to upregulating the expression of
ABCA1 and ABCG1 in THP-1 macrophage-derived foam
cells. Similarly, Lin et al. [20] reported that FGF21 pro-
moted cholesterol efflux and ABCA1 expression in THP1
macrophage-derived foam cells in a dose- and time-
dependent manner. While the mechanisms of how FGF21
increases ABCA1 and ABCG1 expression have not been
completely clarified.
Hypothesis
Sterol regulatory element–binding proteins (SREBPs) are
a family of membrane-bound transcription factors that
mainly regulate lipid homeostasis [21]. SREBPs have two
isoforms including SREBP-1 and SREBP-2. Generally,
SREBP-1 is induced by insulin resistance or hyperinsuline-
mia that leads to fatty acid and triglycerides synthesis,
while SREBP-2 increases endogenous cholesterol synthesis
[21]. Intriguingly, the two members of miR-33, miR-33a
and miR-33b, are respectively located within the intron 16
of SREBP-2 and the intron 17 of SREBP-1 genes [22]. And
miR-33 was reported to maintain cellular lipid level and
cholesterol export by co-expressing with SREBPs gene
[23]. Hence, regulators decreasing SREBPs expression are
also considered as inhibitors of miR-33.
More interestingly, recent findings indicated that
FGF21 regulate cholesterol efflux by targeting SREBP-2
gene. Lin et al. [24] investigated the function of FGF21
in atherosclerosis. And they found that FGF21 deficiency
caused a markedly increasing mortality of apoE-/- mice
and exacerbation of atherosclerosis followed by signifi-
cantly worsened lipid profile and inflammatory cyto-
kines. In mechanism, they found that SREBP-2 was
FGF21 targeted gene to regulate cholesterol efflux.
Therefore, we speculate that FGF21 could inhibit
SREBPs expression as well as the expression of miR-33.
Together, we hypothesis that FGF21 potentially
inhibits miR-33 expression, and thereby enhancing
macrophage related cholesterol efflux and increasing
anti-inflammatory macrophages to prevent atheroscler-
osis (Fig. 1). This hypothesis aims to reveal a new poten-
tial mechanism of FGF21-induced anti-atherosclerosis
by promoting macrophage actions. Besides, this hypoth-
esis also try to provide new research directions for the
conflicting findings of miR-33. As previously described,
the function of miR-33-induced lipid-lowering and anti-
atherosclerosis was in dispute due to several studies did
not observed anti-atherosclerotic effects or even found
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elevated triglyceride levels. But Näär et al. [25] consid-
ered that this result might be partly related to miR-33b
coexpressing with SREBP-1, which is a gene involving in
insulin resistance and the feedback mechanism should
responsible for the increased triglycerides level. Al-
though it was reported FGF21 not only influenced
SREBP-2 but also regulated SREBP-1 [26], FGF21 in-
duced cholesterol efflux was mainly regulated SREBP-2
but not affected SREBP-1 [24]. Thus, studies to discuss
the role of FGF21 in cholesterol export and macrophage
behaviors may make more sense.
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